Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

T-ALL/LBL are challenging hematologic cancers with high rates of relapse and mortality. WU-CART-007 is a CD7-targeted CAR-T cell product with CRISPR/Cas9 deletion of CD7 and T-cell receptor alpha constant (TRAC), to prevent fratricide and enable the use of allogeneic T-cells, respectively (Leedom et al. ASH 2021). This off-the-shelf allogeneic CAR-T cell product is being developed for the treatment of R/R T-ALL/LBL in an ongoing global first-in-human, Phase 1/2 single-agent study (NCT04984356).The RP2D of WU-CART-007 is 900 million (M) cells administered on day 1 following lymphodepleting chemotherapy (LDC).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Armin Ghobadi, Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel, Dr. Dholaria Bhagirathbhai, Rawan G Faramand, Ryan J. Mattison, Michael P. Rettig, Kenneth Jacobs, Ouiam Bakkacha, John Muth, Angela Pannunzio, Angela Pannunzio, Tags: 18 Source Type: research